• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

University of Dundee - Articles and news items

University of Dundee Logo

Ubiquigent and University of Dundee announce collaboration to develop novel ubiquitin system targeted compound libraries

Industry news / 8 October 2014 / Ubiquigent and University of Dundee

Agreement brings together expertise to design, develop and market small molecule libraries targeting ubiquitin system proteins…

University of Dundee Logo

BioCity Scotland announced as UK hub for major European drug discovery project

Industry news, News / 7 February 2013 / University of Dundee

“We are absolutely delighted that the European Lead Factory will be co-located in Scotland…”

University of Dundee Logo

Academia-pharma collaboration attracts £14.4million funding in the UK to accelerate drug discovery

Industry news, News / 14 May 2012 / University of Dundee

The consortium includes six companies & will provide core support of £14.4 million…

Figure 1

Turn back the clock and be healed Induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine

Genomics, Issue 2 2010 / 9 May 2010 / Paul D. Andrews, Drug Discovery Unit, College of Life Sciences, University of Dundee

They are only four years old and are getting everyone very excited; they were Science Magazine’s ‘Breakthrough of the Year 2008’ and Nature’s ‘Method of the Year 2009.’ Their discoverer, Shinya Yamanaka, shared the Lasker Award last year and is no doubt touted for a future Nobel Prize. ‘They’ are induced pluripotent stem cells (or iPS for short). The discovery was that somatic cells from the adult body, whether from a hair, skin biopsy, cord-blood or even adipose tissue, can quite readily be changed back into pluripotent stem cells – ostensibly the state they were in shortly after conception – in the process, erasing the epigenetic modifications that make a brain cell different from, say, a liver cell.

Stem Cells Roundtable

Issue 2 2009, Past issues / 20 March 2009 /

1. What do you feel are the current changing attitudes to Stem Cell Research?

Paul Andrews: First of all are we talking throughout this roundtable about human stem cells? Are we differentiating between human embryonic stem cells and adult stem cells, or patient-derived induced pluripotent stem (iPS) cells? The differences in attitude and responses could be completely different. In addition: what do we mean by research: research aimed at therapy; for drug testing that might reduce reliance on animal models and lead to better drug safety; or basic cell biology research?

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +